Biogen will soon extend its contract pharmacy restrictions to non-hospital covered entities, while Novartis will require hospitals to submit claims [...] …
Blog Posts
Michigan’s legislative session concluded in disarray last week after the House abruptly adjourned without enough members present to vote on [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A federal judge’s recent ruling against West Virginia’s 340B contract pharmacy law advances the drug industry’s push to bring the [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Washington state could see greater cost reductions under a Medicaid fee-for-service pharmacy reimbursement model for 340B providers than through Medicaid [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Contract pharmacy restrictions—and legislation to override them—dominated 340B policy discussions in statehouses and courtrooms across the country this year, as [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
From drugmakers proposing new controversial 340B rebate models to federal lawmakers unveiling their first draft of a bipartisan-backed proposal to [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
U.S. Rep. Earl “Buddy” Carter (R-Ga.), a pharmacist who has advocated for major changes to the 340B program which many [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
U.S. House Republican leaders this week unveiled and then quickly backed off of a year-end federal spending package following internal [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The 119th Congress’ House Energy and Commerce (E&C) Committee—an influential panel with jurisdiction over the Medicaid and 340B programs—will feature [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
The 340B program continues to be a central topic of discussion in the pharmaceutical landscape, especially as specialty medications become an increasing portion of healthcare spending. Specialty pharmacies, covered entities (CEs), and manufacturers are navigating a complex environment shaped by regulatory updates, financial
…